证券之星消息，惠泰医疗近日即将发布2025年年报，根据2月26日发布的业绩快报，归属净利润盈利 8.206亿元，同比增长21.91%。 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 该股最近90天内共有5家机构给出评级，买入评级4家，增持评级1家。 惠泰医疗（688617）主营业务：公司是一家专注于电生理和血管介入医疗器械的研发、生产和销售的高 新技术企业,已形成了以完整冠脉通路和电生理医疗器械为主导,外周血管和神经介入医疗器械为重点发 展方向的业务布局。 ...

报告期内影响经营业绩的主要原因：（1）公司持续深化市场开拓，持续开展各类市场推广活动，积极 发挥研发、技术、质量、市场、渠道等多方面经营优势，不断加深渠道联动，实现产品覆盖率及入院率 的进一步提升；（2）公司始终重视费用管控，研发及销售费用投入聚焦于PFA等核心产品的市场推 广、临床验证及下一代产品研发迭代，通过精细化运营、规模化运行，优化开支结构与节奏，实现净利 润与营收的协同增长。 格隆汇2月26日丨惠泰医疗(688617.SH)公布2025年度业绩快报，报告期内，公司实现营业收入25.84亿 元，较上年同期增长25.08%；归属于母公司所有者的净利润8.21亿元，较上年同期增长21.91%；归属于 母公司所有者的扣除非经常性损益的净利润7.91亿元，较上年同期增长23.00%； ...

深圳惠泰医疗器械股份有限公司 2025 年度业绩快报公告 证券代码：688617 证券简称：惠泰医疗 公告编号：2026-007 | 项目 | 本报告期 | 上年同期 | 增减变动幅 度（％） | | --- | --- | --- | --- | | 营业总收入 | 2,583,927,321.09 | 2,065,801,597.74 | 25.08 | | 营业利润 | 943,928,555.84 | 753,691,427.41 | 25.24 | | 利润总额 | 936,290,399.51 | 745,967,278.53 | 25.51 | | 归属于母公司所有者的净利润 | 820,636,582.43 | 673,151,713.17 | 21.91 | | 归属于母公司所有者的扣除非经 常性损益的净利润 | 790,875,930.28 | 643,008,371.94 | 23.00 | | 基本每股收益（元） | 5.82 | 4.80 | 21.25 | | 加权平均净资产收益率 | 28.77% | 30.35% | 减少 个 1.58 百分点 | | | 本报告期末 | 本报 ...

摘要 ■ 投资逻辑 基于大模型对券商年度展望的全面解析 每年的年底到年初，各券商会密集发布关于总量、行业等年度报告。对投资者而言，难以整合大量研报信息从而提取共识点，此外分歧点也同样缺乏量化 对比。大模型工具的出现解决了这一难点，大模型可以帮助分析师快速完成研报数据预处理、观点精准抓取与分类；大模型通过确定共识点与分歧点的判 定规则，系统整合分散观点，量化呈现各券商对板块不同观点的支持率，清晰核心分歧维度。本次研究以大模型为核心分析工具，全面剖析2026年各大板 块年度展望，梳理宏观、策略、固收及七大细分行业的共识与分歧，为投资者提供高效精准的决策参考。 总量观点总结 对于总量观点，我们分别从宏观经济、年度策略、固定收益三个方面分别剖析了各券商分析师的年度展望。 在宏观经济方面，大多数券商认为随着"十五五"政策发力，2026年GDP目标为5%左右；CPI、PPI从低位逐步修复，国内通货膨胀的压力得到缓解；货币 政策维持适度宽松基调，流动性保持合理充裕；财政政策延续积极取向，赤字率维持合理高位；出口保持稳健，贸易顺差维持历史较高水平；国外环境虽 然出现波动，但整体风险可控。 作者：高智威、许坤圣 在年度策略方面 ...

Core Insights - The China Securities Medicine and Medical Device Innovation Index (931484) shows mixed performance among its constituent stocks, with New and Achieve leading the gains at 3.63% [1] - The Medical Innovation ETF (516820) has seen a net inflow of 12.6971 million yuan over the past three days, with a peak single-day inflow of 6.1732 million yuan [1] - The current phase of brain-computer interface technology is described as an explosive period, with multiple countries, including China, accelerating their strategic positioning in global brain science [1] - AI is transitioning from a supportive role to becoming a core driver of value reconstruction and efficiency revolution in the medical industry, impacting various sectors such as medical imaging and drug development [1] Industry Overview - The Medical Innovation ETF closely tracks the China Securities Medicine and Medical Device Innovation Index, which selects 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors [2] - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray, and Hengrui Medicine, collectively accounting for 63.9% of the index [2]

截至2026年2月26日 09:56，中证医药及医疗器械创新指数(931484)成分股方面涨跌互现，新和成领涨 4.59%，爱博医疗上涨2.03%，锦波生物上涨0.40%；惠泰医疗领跌。医疗创新ETF(516820)最新报价0.36 元。 从资金净流入方面来看，医疗创新ETF近3天获得连续资金净流入，最高单日获得617.32万元净流入， 合计"吸金"1269.71万元，日均净流入达423.24万元。（数据来源：Wind） 消息面上，2026年，中国创新药对外BD交易（商务拓展交易）持续升温、势头强劲。医药魔方 NextPharma数据库显示，截至2月25日，年内中国创新药已发生44起对外授权（license-out）交易事件， 首付款约为31.23亿美元，总金额达532.76亿美元。 江海证券指出，2026年中国创新药BD呈现三大转型：技术输出联合产品授权、平台化合作、全球并跑 创新。建议关注小核酸（递送技术/慢病管线）、肿瘤免疫（双抗/ADC联用）、代谢疾病（GLP-1改良 品种/MASH肝靶向siRNA）、CGT（体内基因编辑/通用型CAR-T）等核心赛道，重点评估平台造血能 力（如年输出管线数）、临床里 ...

Market Overview - The Shanghai Composite Index increased by 0.41% to close at 4082.07 points, with a weekly high of 4142.56 points [1] - The Shenzhen Component Index rose by 1.39% to 14100.19 points, reaching a peak of 14296.48 points [1] - The ChiNext Index saw a 1.22% increase, closing at 3275.96 points, with a high of 3348.48 points [1] - In the global market, the Nasdaq Composite fell by 2.1%, the Dow Jones Industrial Average decreased by 1.23%, and the S&P 500 dropped by 1.39% [1] - In the Asia-Pacific region, the Hang Seng Index rose by 0.03%, while the Nikkei 225 Index increased by 4.96% [1] New Stock Issuance - Two new stocks were issued during the week: Tongbao Optoelectronics (920168.BJ) on February 9, 2026, and Tongling Technology (920187.BJ) on February 11, 2026 [2] Margin Trading - The total margin trading balance in the Shanghai and Shenzhen markets was 25,797.58 billion yuan, with a financing balance of 25,640.12 billion yuan and a securities lending balance of 157.46 billion yuan [3] - The margin trading balance decreased by 752.4 billion yuan compared to the previous week [3] - The Shanghai market's margin trading balance was 13,113.7 billion yuan, down by 356.66 billion yuan, while the Shenzhen market's balance was 12,683.88 billion yuan, down by 395.74 billion yuan [3] - A total of 3,486 stocks had margin buying, with 184 stocks having over 1 billion yuan in buying amounts, led by Xinyi Technology (103.25 billion yuan), Zhongji Xuchuang (98.63 billion yuan), and Wangsu Science and Technology (74.22 billion yuan) [3] Fund Issuance - Seven new funds were issued during the week, including Guoshou Anbao Enhanced Return Bond E, Huafu Anhua Bond D, Dongfanghong Monetary F, Bank of China Health Life Mixed C, Huitianfu Tiantianle Double Win Bond E, Nuoan Selected Return Mixed C, and Changsheng Electronic Information Theme Mixed C [5] Share Buybacks - Eight companies announced share buybacks, with the highest amounts executed by Luxshare Precision (002475), Hengyi Petrochemical (000703), Linyang Energy (601222), Kaiying Network (002517), and Huitai Medical (688617) [7] - The industries with the highest buyback amounts were electronics, petroleum and petrochemicals, and public utilities [8]

这家智慧招采领域的龙头企业累计回购股份182.72万股，占公司总股本的0.57%，回购成交的最高价为31.15元/股，最低价为24.21元/股，回购均价为27.01元/ 股，支付的资金总额达到4935.67万元。 回购方案于2025年9月24日启动，计划使用自有资金3000万元至5000万元，实际执行金额接近上限。 这些回购的股份将全部用于员工持股计划或股权激励。 春节前的资本市场总是充满变数，当港股市场特别是互联网科技股表现疲软时，A股市场却出现了另一番景象。 2026年1月下旬至2月上旬，就在春节假期临近之际，9家行业龙头公司不约而同地采取了行动。 新点软件在2026年2月13日发布公告，宣布公司已完成股份回购计划。 回购的股份将在未来用于股权激励、员工持股计划或转换公司可转债。 衢州东峰新材料集团在2026年2月12日披露了回购报告书。 这家国资控股的新材料与医药包装企业计划使用自有资金，通过集中竞价交易方式回购公司股 份，回购金额区间为5000万元至1亿元。 回购价格上限设定为6.48元/股，按照这个价格测算，预计回购股份数量约为771.60万股至1543.21万股，占公司总股 本的比例为0.40%至 ...

Group 1 - The company plans to repurchase shares using its own funds, with an amount between 150 million to 200 million yuan, aimed at employee incentives and enhancing investor confidence [1] - The first repurchase was executed on February 11, 2026, with 77,000 shares bought back at a total cost of approximately 18.61 million yuan [1] - The recent opening of the national drug procurement may have indirect effects on the medical device industry, although the company's core business focuses on electrophysiology and interventional devices [1] Group 2 - Huayuan Securities initiated coverage on the company on February 13, 2026, giving it a "buy" rating, with expected compound annual growth rates for revenue and net profit exceeding 24% from 2025 to 2027 [2] - In the past 90 days, four institutions have rated the company, with three giving a "buy" and one an "overweight" rating, indicating positive expectations from analysts [2]

Core Viewpoint - The medical innovation sector is experiencing growth, highlighted by the successful debut of China's first fully self-developed orthopedic surgical robot, indicating advancements in medical technology and potential investment opportunities in the sector [1][2]. Group 1: Market Performance - As of February 12, 2026, the CSI Medical and Medical Device Innovation Index (931484) increased by 0.05%, with notable gains from companies such as WuXi AppTec (up 3.39%) and Kanglong Chemical (up 1.37%) [1]. - The Medical Innovation ETF (516820) is currently priced at 0.37 yuan, with a trading volume of 794.40 million yuan and a turnover rate of 0.42% [1]. - Over the past month, the average daily trading volume of the Medical Innovation ETF was 65.14 million yuan [1]. Group 2: Industry Insights - CITIC Securities believes that surgical robots represent one of the best business models in the medical device sector, as installed equipment will drive continuous consumption of consumables, leading to stable revenue and cash flow [2]. - The global market for surgical robots is estimated to exceed 1 trillion yuan, with significant growth potential in penetration rates and market size [2]. - Domestic leaders in the surgical robot market are accelerating product iterations, achieving performance levels close to global leaders, and have a substantial portion of their revenue from overseas markets, which are experiencing high growth [2]. - AI is expected to empower surgical robots to achieve autonomous operations, further assisting or replacing some surgical procedures performed by doctors, which will benefit industry penetration rates and enhance company valuations [2]. Group 3: Index Composition - The CSI Medical and Medical Device Innovation Index comprises 30 publicly listed companies with strong profitability, growth potential, and research innovation capabilities, reflecting the overall performance of the medical and medical device sector [2]. - As of January 30, 2026, the top ten weighted stocks in the index include WuXi AppTec, Mindray Medical, and Heng Rui Medicine, collectively accounting for 63.9% of the index [2].